SEC Form 4 · accession 0001104659-17-034708
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Aryeh
Director
Period of report
May 19, 2017
Accepted (ET)
May 24, 2017 · 6:07 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF1,F2,F3 | May 19, 2017 | S | 51,041 | $1.5587 | D | 337,644 | I | By JALAA Equities, LP |
| Common Shares, without par valueF4,F3 | May 22, 2017 | S | 233,468 | $1.4236 | D | 104,176 | I | By JALAA Equities, LP |
| Common Shares, without par valueF5,F3 | May 23, 2017 | S | 104,176 | $1.4099 | D | 0 | I | By JALAA Equities, LP |
| Common Shares, without par value | holding | — | — | — | 15,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2Includes 45,469 shares issued in connection with a previously exercised warrant.
- F3Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
- F4This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.